Difference between revisions of "Diffuse large B-cell lymphoma - historical"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
(Created page with "'''Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.''' The p...")
 
Line 12: Line 12:
  
 
=Untreated=
 
=Untreated=
 +
 +
==CCOP {{#subobject:9a2b69|Regimen=1}}==
 +
{| class="wikitable" style="float:right; margin-left: 5px;"
 +
|-
 +
|[[#toc|back to top]]
 +
|}
 +
CDOP: '''<u>C</u>'''yclophosphamide, '''<u>C</u>'''aelyx (Liposomal Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone
 +
 +
===Regimen {{#subobject:4efe2a|Variant=1}}===
 +
{| border="1" style="text-align:center;" !align="left"
 +
|'''Study'''
 +
|[[Levels_of_Evidence#Evidence|'''Evidence''']]
 +
|-
 +
|[http://www.haematologica.org/content/87/8/822.long Martino et al. 2002]
 +
|<span
 +
style="background:#EEEE00;
 +
padding:3px 6px 3px 6px;
 +
border-color:black;
 +
border-width:2px;
 +
border-style:solid;">Phase II</span>
 +
|-
 +
|}
 +
 +
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m2 IV once over 30 minutes on day 1
 +
*[[Doxorubicin liposomal (Doxil)]] 30 mg/m2 IV once over 1 hour on day 1
 +
*[[Vincristine (Oncovin)]] 2 IV once over 15 minutes on day 1
 +
*[[Prednisone (Sterapred)]] 60 mg/m2 PO once per day on days 1 to 5
 +
 +
'''21-day cycles x 6 to 8 cycles'''
 +
 +
===References===
 +
# Martino R, Perea G, Caballero MD, Mateos MV, Ribera JM, de Oteyza JP, Arranz R, Terol MJ, Sierra J, San Miguel JF. Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: results from a prospective phase II study. Haematologica. 2002 Aug;87(8):822-7. [http://www.haematologica.org/content/87/8/822.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/12161358 PubMed]
  
 
=Relapsed/refractory=
 
=Relapsed/refractory=

Revision as of 15:48, 11 March 2015

Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.

The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines.

67 regimens on this page
85 variants on this page


Untreated

CCOP

back to top

CDOP: Cyclophosphamide, Caelyx (Liposomal Doxorubicin), Oncovin (Vincristine), Prednisone

Regimen

Study Evidence
Martino et al. 2002 Phase II

21-day cycles x 6 to 8 cycles

References

  1. Martino R, Perea G, Caballero MD, Mateos MV, Ribera JM, de Oteyza JP, Arranz R, Terol MJ, Sierra J, San Miguel JF. Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: results from a prospective phase II study. Haematologica. 2002 Aug;87(8):822-7. link to original article contains verified protocol PubMed

Relapsed/refractory

ESHA

back to top

ESHA: Etoposide, Solumedrol (Methylprednisolone) High-dose Ara-C (Cytarabine)

Regimen

Study Evidence Comparator Efficacy
Velasquez et al. 1994 Phase III ESHAP Inferior RR

Supportive medications:

21 to 28 day cycles ("after recovery of the toxic effects") x 6 to 8 cycles

References

  1. Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA, Romaguera J, Rubenstein E, Cabanillas F. ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol. 1994 Jun;12(6):1169-76. link to original article contains verified protocol PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Diffuse_large_B-cell_lymphoma_-_historical&oldid=7586"